GlassScriptPhysician profile
Mary Harding
NPI 1639557531
$4,807.07
in general payments reported to CMS, 2019-2025
39 companies · $50.29 in 2025
The $50.29 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,442 · 2022: $2,193 · 2023: $1,122 · 2025: $50.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $725.02 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $658.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $489.25 | 2021-2023 | |
| Amgen INC. | $295.54 | 2021-2023 | Evenity, Prolia, Otezla |
| Amarin Pharma, INC. | $252.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.42 | 2021-2023 | |
| Lilly USA, LLC | $201.99 | 2021-2023 | Jardiance, Trulicity, Mounjaro |
| Janssen Pharmaceuticals, INC | $180.94 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $180.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $176.93 | 2021-2023 | Belsomra, Verquvo |
| Novartis Pharmaceuticals Corporation | $124.15 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $115.50 | 2022 | |
| Daiichi Sankyo INC. | $107.07 | 2021-2022 | |
| Corium, LLC | $101.40 | 2023 | Adlarity |
| Sumitomo Pharma America, INC. | $96.11 | 2023 | Gemtesa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.